Literature DB >> 11407698

Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression.

M Galindo1, B Santiago, M Rivero, J Rullas, J Alcami, J L Pablos.   

Abstract

OBJECTIVE: Chemokines are important mediators in the chemoattraction of leukocytes to sites of inflammation. This study investigated the potential contribution of systemic sclerosis (SSc) fibroblasts to chemokine production and its potential relevance to the pathogenesis of SSc.
METHODS: The expression of messenger RNA (mRNA) for different C-C and C-X-C chemokines by SSc and normal fibroblasts was studied by RNase protection assay. Monocyte chemoattractant protein 1 (MCP-1) protein production was analyzed by enzyme-linked immunosorbent assay. The chemotactic effect of fibroblast-derived MCP-1 on monocytic cells was analyzed in a transmigration assay. Nuclear factor kappaB (NF-kappaB) and activator protein 1 (AP-1) activation in fibroblasts was studied by electromobility shift analysis. MCP-1 expression in SSc skin sections was studied by immunohistochemistry.
RESULTS: Among all chemokine genes studied, only MCP-1 and interleukin-8 mRNA were expressed by nonstimulated normal and SSc fibroblasts. SSc fibroblasts displayed increased constitutive expression of MCP-1 mRNA and protein and showed a blunted response to oxidative stress. Increased MCP-1 production was associated with higher chemotactic activity for monocytic cells. Increased NF-kappaB or AP-1 activation was not responsible for the constitutive overexpression of MCP-1 by SSc fibroblasts. In SSc skin sections, MCP-1 expression was detected in fibroblasts, keratinocytes, and mononuclear cells, whereas it was undetectable in normal skin.
CONCLUSION: SSc fibroblasts display a specific pattern of chemokine gene expression that is characterized by constitutively increased and abnormally regulated expression of MCP-1 in vitro. MCP-1 is also expressed in lesional skin and can participate in the pathogenesis of SSc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407698     DOI: 10.1002/1529-0131(200106)44:6<1382::AID-ART231>3.0.CO;2-T

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

Review 1.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

Review 2.  Update on macrophages and innate immunity in scleroderma.

Authors:  Jennifer J Chia; Theresa T Lu
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

3.  Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Authors:  Minoru Hasegawa; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2010-11-04       Impact factor: 2.980

4.  Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.

Authors:  Matthew B Greenblatt; Jennifer L Sargent; Giuseppina Farina; Kelly Tsang; Robert Lafyatis; Laurie H Glimcher; Michael L Whitfield; Antonios O Aliprantis
Journal:  Am J Pathol       Date:  2012-01-11       Impact factor: 4.307

5.  Up regulated expression of tumour necrosis factor {alpha} converting enzyme in peripheral monocytes of patients with early systemic sclerosis.

Authors:  T Bohgaki; Y Amasaki; N Nishimura; M Bohgaki; Y Yamashita; M Nishio; K-I Sawada; S Jodo; T Atsumi; T Koike
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

6.  Vaccinia vaccine-based immunotherapy arrests and reverses established pulmonary fibrosis.

Authors:  Samuel L Collins; Yee Chan-Li; MinHee Oh; Christine L Vigeland; Nathachit Limjunyawong; Wayne Mitzner; Jonathan D Powell; Maureen R Horton
Journal:  JCI Insight       Date:  2016-04-07

7.  Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis.

Authors:  Giuseppina A Farina; Michael R York; Michael Di Marzio; Cindy A Collins; Stephan Meller; Bernhard Homey; Ian R Rifkin; Ann Marshak-Rothstein; Timothy R D J Radstake; Robert Lafyatis
Journal:  J Invest Dermatol       Date:  2010-07-08       Impact factor: 8.551

8.  Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil.

Authors:  Léa Castellucci; Sarra E Jamieson; Lucas Almeida; Joyce Oliveira; Luiz Henrique Guimarães; Marcus Lessa; Michaela Fakiola; Amélia Ribeiro de Jesus; E Nancy Miller; Edgar M Carvalho; Jenefer M Blackwell
Journal:  Infect Genet Evol       Date:  2012-03-28       Impact factor: 3.342

9.  Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.

Authors:  Allison L Mathes; Romy B Christmann; Giuseppina Stifano; Alsya J Affandi; Timothy R D J Radstake; G Alessandra Farina; Cristina Padilla; Sarah McLaughlin; Robert Lafyatis
Journal:  Ann Rheum Dis       Date:  2013-07-19       Impact factor: 19.103

10.  Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis.

Authors:  E Selvi; S A Tripodi; M Catenaccio; S Lorenzini; D Chindamo; S Manganelli; R Romagnoli; F Ietta; L Paulesu; C Miracco; M Cintorino; R Marcolongo
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.